NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free HZNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$116.30▼$116.3050-Day Range$112.60▼$116.3052-Week Range$60.03▼$116.38VolumeN/AAverage Volume2.50 million shsMarket Capitalization$26.63 billionP/E Ratio62.19Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial MediaSustainability Get Horizon Therapeutics Public alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Horizon Therapeutics Public Stock (NASDAQ:HZNP)Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy HZNP Stock News HeadlinesDecember 21, 2023 | seekingalpha.com5 Biotech Acquisition Targets To Accumulate In 2024November 16, 2023 | msn.comNasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationMarch 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 24, 2023 | chicago.suntimes.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionOctober 24, 2023 | msn.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 6, 2023 | finance.yahoo.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 5, 2023 | stocknews.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberOctober 5, 2023 | stockhouse.comRule 17(d) Announcement - Horizon Therapeutics plcMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: October 5, 2023 | finance.yahoo.comRule 17(d) Announcement – Horizon Therapeutics plcOctober 2, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023September 26, 2023 | benzinga.comBoard Member at Horizon Therapeutics Exercises Options Worth $2.31MSeptember 26, 2023 | finance.yahoo.comHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustrySeptember 19, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 13, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 5, 2023 | finance.yahoo.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSeptember 4, 2023 | benzinga.comHere's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth TodaySeptember 1, 2023 | finanznachrichten.deHorizon Therapeutics plc and Amgen: Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close AcquisitionAugust 28, 2023 | finance.yahoo.comFTC suspends challenge to Amgen-Horizon Therapeutics dealAugust 26, 2023 | reuters.comUS FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon TherapeuticsAugust 23, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy GroupsAugust 16, 2023 | seekingalpha.comHorizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?August 16, 2023 | seekingalpha.comImproved Outlook For Horizon Therapeutics And AmgenAugust 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)August 9, 2023 | markets.businessinsider.comHorizon Therapeutics (HZNP) Receives a Hold from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comHorizon Therapeutics plc Reports Second-Quarter 2023 Financial ResultsSee More Headlines Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2023Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio62.19 Forward P/E Ratio27.76 P/E Growth3.96Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.63 billion Price / Sales7.34 Cash Flow$7.05 per share Price / Cash Flow16.49 Book Value$22.38 per share Price / Book5.20Miscellaneous Outstanding Shares228,990,000Free Float223,957,000Market Cap$26.63 billion OptionableOptionable Beta1.03 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Timothy P. Walbert (Age 56)Chairman, Pres & CEO Comp: $3.5MMr. Aaron L. Cox (Age 40)Exec. VP of Fin. & CFO Comp: $1.36MMr. Sean M. Clayton J.D. (Age 44)Exec. VP & Gen. Counsel Comp: $7.03MMr. Andy Pasternak (Age 52)Exec. VP & Chief Strategy Officer Comp: $1.4MDr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Exec. VP of R&D Comp: $3.66MMr. Patrick McIlvenny (Age 44)Sr. VP & Chief Accounting Officer Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerMr. Geoffrey M. Curtis (Age 48)Exec. VP of Corp. Affairs & Chief Communications Officer Ms. Keli WalbertExec. VP & Chief Marketing OfficerMs. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEOMore ExecutivesKey CompetitorsRoyalty PharmaNASDAQ:RPRXAlexion PharmaceuticalsNASDAQ:ALXNMyoKardiaNASDAQ:MYOKJazz PharmaceuticalsNASDAQ:JAZZMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInstitutional OwnershipGlazer Capital LLCSold 1,000 shares on 2/15/2024Ownership: 0.000%Prelude Capital Management LLCSold 32,600 shares on 2/15/2024Ownership: 0.000%Parallax Volatility Advisers L.P.Sold 79,800 shares on 2/15/2024Ownership: 0.000%Clear Street Markets LLCSold 216,000 shares on 2/15/2024Ownership: 0.000%Westchester Capital Management LLCSold 276,000 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Wednesday, March 13, 2024 at 11:24 PM. Pros Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited: Horizon Therapeutics has a diverse portfolio of 12 medicines targeting rare diseases, gout, ophthalmology, and inflammation, providing revenue stability and growth potential. The company has collaboration agreements with various biopharmaceutical companies, enhancing its research and development capabilities and potential for innovative drug discoveries. Recent reports indicate that Olympiad Research LP increased its holdings in Horizon Therapeutics, suggesting confidence in the company's future performance. Horizon Therapeutics' focus on addressing critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases aligns with growing healthcare demands and market opportunities. The company's strategic name change in 2019 to Horizon Therapeutics Public Limited reflects a rebranding effort that may positively impact its market perception and investor confidence. Cons Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons: Market volatility and regulatory challenges in the pharmaceutical industry can impact Horizon Therapeutics' stock price and financial performance. Competition in the pharmaceutical market is intense, with other companies also focusing on rare diseases and inflammation, potentially affecting Horizon Therapeutics' market share and profitability. Investing in biopharmaceutical companies like Horizon Therapeutics carries inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new drugs. Global economic conditions and healthcare policies can influence the demand for Horizon Therapeutics' products, affecting its revenue streams and growth prospects. Changes in healthcare reimbursement policies or pricing regulations may impact the profitability of Horizon Therapeutics' products and overall financial performance. HZNP Stock Analysis - Frequently Asked Questions Should I buy or sell Horizon Therapeutics Public stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares. View HZNP analyst ratings or view top-rated stocks. How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 earnings per share. What ETFs hold Horizon Therapeutics Public's stock? ETFs with the largest weight of Horizon Therapeutics Public (NASDAQ:HZNP) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), VictoryShares Nasdaq Next 50 ETF (QQQN), ProShares Merger ETF (MRGR), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Hedge Industry VIP ETF (GVIP) and Strategas Global Policy Opportunities ETF (SAGP). What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL). Who are Horizon Therapeutics Public's major shareholders? Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Highbridge Capital Management LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%), Picton Mahoney Asset Management (0.00%), BCK Capital Management LP (0.00%), Simplex Trading LLC (0.00%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert and William F Daniel. View institutional ownership trends. Does Horizon Therapeutics Public have any subsidiaries? The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..Read More This page (NASDAQ:HZNP) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.